Mabylon AG Secures Significant Research Funding
In an exciting turn of events, Mabylon AG has announced it has obtained research grants exceeding CHF 1.3 million. This funding is specifically directed toward breakthrough treatments for amyotrophic lateral sclerosis (ALS) and inflammatory bowel disease (IBD). With this support, the company is solidifying its position at the cutting edge of biopharmaceutical advancements.
Funding Sources and Goals
The grants have been awarded by prominent organizations, including the Innosuisse Swiss Innovation Agency, Target ALS, and the ALS Association. The funds from Target ALS and the ALS Association are particularly aimed at advancing the preclinical development of human-derived TDP-43 intrabodies. These specialized intrabodies strive to restore normal TDP-43 function in ALS patients, thereby reducing harmful TDP-43 aggregates present in damaged neurons.
Importance of TDP-43 in ALS Research
Dr. Kuldip Dave, Senior Vice President of Research at the ALS Association, explains that TDP-43 aggregates are a key characteristic of ALS, which makes them a crucial target for treatments aimed at both familial and sporadic forms of the disease. The financial support will aid Mabylon AG in progressing its promising intrabody approach through the Lawrence and Isabel Barnett Drug Development Program, designed to fast-track the transition from laboratory research to clinical testing.
Advancements in IBD Treatments
At the same time, Innosuisse has allocated CHF 0.8 million for the advancement of Mabylon's MY012 program, which aims to develop an antibody therapy targeting inflammasomes for inflammatory bowel disease. This initiative aims to provide improved efficacy and safety compared to current treatments, marking a significant step forward in addressing the serious health issues linked to IBD.
Innovative Research Approaches
Dr. Niccolò Pengo, Chief Scientific Officer at Mabylon, emphasized that their research is built on discovering naturally occurring antibodies from diverse patient groups or immunized animals. This approach has effectively led to the identification of promising antibody candidates, marking the grants as a strong endorsement of the potential impact that Mabylon’s research could have.
Future Clinical Development Plans
There's a palpable sense of excitement at Mabylon AG, with CEO Alcide Barberis expressing gratitude for the financial backing that will help fast-track preclinical proof-of-concept for both the ALS and IBD projects. The strategic aim is to move these initiatives toward clinical development, possibly in collaboration with established biopharmaceutical companies or by creating dedicated spin-off ventures.
Focus on Allergy Treatments
Interestingly, Mabylon is also dedicated to advancing an anti-allergen antibody product candidate. They've recently made progress with a multi-specific anti-allergen antibody targeting peanut allergies, which is currently in the Investigative New Drug (IND) studies. Their partnership with Pfizer through the Pfizer Ignite program further highlights their commitment to confronting allergy-related health problems.
About Mabylon AG
Mabylon is an innovative Swiss biotechnology firm focused on harnessing the therapeutic power of naturally occurring human antibodies. Their work includes addressing allergies, neurodegenerative diseases, and inflammatory conditions. Human-derived antibodies offer a notable advantage, showing greater therapeutic potential compared to traditional methods that rely on humanized animal models or artificial libraries.
By capturing antibodies from allergic patients, Mabylon enhances the understanding of allergenic epitopes and their role in disease progression, paving the way for more effective treatments.
Contact Information
Mabylon AG
Wagistrasse 14
8952 Schlieren, Switzerland
Contact:
Alcide Barberis, CEO
Tel: +41 40 88 16 59 64
Frequently Asked Questions
What is Mabylon AG known for?
Mabylon AG is known for its innovative research in developing human-derived antibodies aimed at addressing health issues like allergies and neurodegenerative diseases.
What diseases are Mabylon's research grants targeting?
The research grants specifically focus on advancing treatments for amyotrophic lateral sclerosis (ALS) and inflammatory bowel disease (IBD).
Which organizations provided funding to Mabylon AG?
The funding has been granted by well-known organizations such as the Innosuisse Swiss Innovation Agency, Target ALS, and the ALS Association.
What is the significance of TDP-43 in ALS research?
TDP-43 aggregates play a crucial role in the pathology of ALS, making them a vital focus for potential therapies aimed at improving patient outcomes.
Is Mabylon involved in allergy treatment development?
Yes, Mabylon is actively developing an anti-allergen antibody product to treat peanut allergies and has partnered with Pfizer for this initiative.
